Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000797790 | SCV000937369 | pathogenic | Ehlers-Danlos syndrome, type 4 | 2022-08-16 | criteria provided, single submitter | clinical testing | This variant is not present in population databases (gnomAD no frequency). For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the COL3A1 protein in which other variant(s) (p.Phe1456Leu) have been determined to be pathogenic (Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. ClinVar contains an entry for this variant (Variation ID: 643968). This premature translational stop signal has been observed in individual(s) with clinical features of vascular Ehlers-Danlos syndrome (PMID: 31126764). This sequence change creates a premature translational stop signal (p.Gln1454*) in the COL3A1 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 13 amino acid(s) of the COL3A1 protein. |